X

Drug Profile

YH 015

Alternative Names: YH-015

Latest Information Update: 24 Apr 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Beijing Biocytogen
Class Anti-inflammatories; Monoclonal antibodies
Mechanism of Action CD40 antigen inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Autoimmune disorders

Most Recent Events

14 Apr 2023 Beijing Biocytogen has patent protection for genetically modified non-human animals expressing humanized CD40 and its uses in USA and China
14 Apr 2023 Preclinical trials in Autoimmune disorders in China (Parenteral) before April 2023 (Beijing Biocytogen pipeline, April 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com